PLCH2 - New-wiki

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	CAMTA1	calmodulin binding transcription activator 1
Novel	CEP104	centrosomal protein 104
Novel	PEX10	peroxisomal biogenesis factor 10	E3 ubiquitin ligases ubiquitinate target proteins Peroxisomal protein import Peroxisomal protein import		Zellweger syndrome spectrum, including: Zellweger syndrome (ZS); Adrenoleukodystrophy, neonatal (NALD); Infantile Refsum disease (IRD)
Novel	TP73-AS1	TP73 antisense RNA 1
	AGTR1	angiotensin II receptor type 1	Peptide ligand-binding receptors G alpha (q) signalling events Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis	Valsartan Olmesartan Losartan Candesartan cilexetil Eprosartan Telmisartan Irbesartan Forasartan Saprisartan Tasosartan CYT006-AngQb Azilsartan medoxomil Fimasartan Angiotensin II Candesartan	Renal tubular dysgenesis
	HRAS	HRas proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants	Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Bladder cancer Penile cancer Squamous cell carcinoma Thyroid cancer Cervical cancer Hepatocellular carcinoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)

Search Results for: PLCH2